B-cell lymphoproliferative disorders (BCLD) have been associated with chronic hepatitis C virus (HCV) infection. The HCV glycoprotein E2 (gpE2) hypervariable region I (HVR-I) may be a potential antigenic candidate to promote B-cell proliferation. The purpose of this study was to analyze the influence of HVR-I sequence variability in the development of BCLD. HVR-I sequences were studied in 29 chronically HCV-infected patients with (n ¼ 15) or without (n ¼ 14) BCLD. After PCR amplification of the gpE2 region, analysis of the 81 bp HVR-I encoding fragment was performed on 7-18 clones per patient. HVR-I sequence complexity was slightly lower in patients with BCLD (mean 0.347) than without (0.468) (P ¼ 0.2), though, sequence diversities were similar (0.0370 vs 0.0954, P ¼ 0.239). Phylogenetic analysis did not reveal any BCLD-associated clustering. In our population, neither the recently described insertion between positions 1 and 2 of HVR-I nor residues at positions 4 and 13 were particularly linked to BCLD. As previously described, we confirm the high degree of conservation of HVR-I residues T-2, G-6 and G-23 in our patients. Contrary to recent findings, our analysis based on multiple clones per patient analysis did not reveal any particular motif associated with BCLD.
Introduction
The main consequence of hepatitis C virus (HCV) infection is chronic hepatitis that may lead to cirrhosis and hepatocellular carcinoma. 1 However, in addition to hepatic disease, HCV infection is also frequently implicated in the development of extrahepatic manifestations. Most of them are related to autoimmune or lymphoproliferative states. A total of 15% of patients with HCV chronic infection develop a type II mixed cryoglobulinemia (MC), a benign disease characterized by an underlying proliferation of monoclonal B cell, which typically secretes a cryoprecipitable immunoglobulin M kappa (IgMk) with rheumatoid factor (RF) activity. [2] [3] [4] Some HCV-MC can evolve into overt B-cell non-Hodgkin lymphoma (B-NHL), suggesting that HCV may play a role in the pathogenesis of clonal proliferation of B cell, which may further evolve into malignant lymphoma. 5, 6 Association between HCV and NHL has been reported in some geographic regions, particularly in Italy, where a high prevalence (9-50%) of chronic HCV infection has been observed among patients with B-NHL. Furthermore, in a recent meta-analysis of case-control studies, Gisbert et al 7 clearly demonstrate a higher HCV prevalence in patients with B-NHL compared to the general population or to patients with other hematological malignancies.
To date, possible mechanisms through which HCV may induce the expansion of particular B-cell clones are still unclear. One of the most plausible pathogenic mechanism is that specific B-cell clones proliferate as a consequence of chronic antigen stimulation exerted by HCV. [8] [9] [10] [11] Analysis of both immunoglobulin receptor of HCV-associated B-NHLs and Ig with RF activity of HCV-associated type II MC suggests, in two recent studies, that the HCV E2 envelope glycoprotein could be the common antigenic stimulus involved in the lymphoproliferative process leading to NHLs and MC development. 12, 13 The HCV E2 envelope protein has been shown to bind human B lymphocytes via the CD81 receptor, a tetraspanin molecule expressed on B-cell surface.
14 It seems that this specific binding can lower B-cell activation threshold and thus facilitate Blymphocyte proliferation. 15 These data support the hypothesis that HCV E2 envelope protein may play a major role in both clonal selection and proliferation (benign or malign) of B cells.
The N-terminal 27 residues of E2 (aa 384-410), designated hypervariable region 1 (HVR-I), display the highest variability within the whole HCV protein-coding region of the genome. HVR-I bears major neutralizing epitopes and its variability plays a major role in the virus escape to the host immune surveillance. [16] [17] [18] [19] Gerotto et al 20 recently reported that particular variations of HVR-I (insertion at codon 385 or deletion at codon 384) are present in a significant proportion of patients with HCV-type II MC (6 out of 21) and absent in all patients with no MC (n ¼ 20). These results suggest that specific HVR-I sequences could play a role in B-cell monoclonal proliferation triggering implicated in the development of HCV-associated benign and malignant lymphoproliferative disorders.
The aim of this study was to assess if specific mutations in HVR-I sequence are selected in patients with HCV-monoclonal B-cell proliferation. B-cell monoclonal expansion was defined by the presence of a type II MC or by the detection of clonal immunoglobulin gene rearrangement in B cells for patients with no MC. We then analyzed and compared HVR-I sequences from this selection of chronically HCV-infected patients, with and without B-cell lymphoproliferative disorders (BCLD).
Patients, materials and methods

Patients
We studied 29 patients chronically infected with HCV, all positive for both antibodies to HCV tested by a third-generation enzyme-linked immunosorbent assay (Monolisa HCV plus, Biorad, Marnes-la-Coquette, France) and serum HCV RNA detected by reverse transcription-polymerase chain reaction (RT-PCR) (Amplicor v2.0, Roche, Meylan, France). The HCV genotype was reported for all patients and assayed with INNOLiPA (Innogenetics, Gent, Belgium). All patients were seronegative for human immunodeficiency virus.
All patients belonged to a large cohort of 115 chronically HCV-infected patients who were prospectively included in a recently published study. 21 Beside the presence or not of a monoclonal B-cell expansion, the selection of 29 patients was solely based on the availability of an adequate volume of wellconserved frozen samples to perform our analyses. Among the 29 patients, 15 patients had a monoclonal B-cell expansion (11 women, four men; median age, 58 years; range 34-74). Monoclonal B-cell expansion was asserted either indirectly by the presence of type II MC (n ¼ 8) or directly by the detection of a monoclonal B-cell population in serum and in liver biopsies of patients with no MC (n ¼ 7). Briefly, this latter method was based on the detection of clonal immunoglobulin heavy chain gene rearrangement in B cells by PCR to amplify the chain determining region 3 (CDR3) using variable region-(VH) and joining (JH) region-specific primers, as previously described. 22, 23 Patients with HCV-type II MC presented with clinical signs of vasculitis, that is, arthralgia (n ¼ 8), peripheral neuropathy (n ¼ 7), skin purpuric lesion (n ¼ 4), and cerebral vasculitis (n ¼ 2). None of the patients presented with clinical evidence of lymphoma at the time of blood sampling.
The control group consisted of 14 patients with no evidence of monoclonal B cell expansion (seven women, seven men; median age, 52 years; range , and no extra hepatic manifestation.
Cloning and sequencing of HVR-I
Total RNA was purified from 140 ml of plasma by a silica particle method (Qiamp Viral RNA, Qiagen, Les Ulis, France) according to manufacturer's instructions and was eluted in 60 ml of AVE buffer. RT was performed at 371C for 60 min in a 25 ml reaction mixture containing 13 ml of purified viral RNA, 2 ml of random hexamers (50 mM), 0.5 mM deoxynucleoside triphosphate (dNTP), 20 mM dithiothreitol, 0.5 U Rnase inhibitor (Promega, Charbonnières, France), 0.5 U Moloney murine leukemia virus reverse transcriptase (Invitrogen, Cergy-Pontoise, France) and 1 Â MMLV buffer (Invitrogen, Cergy-Pontoise, France).
A protocol was designed to amplify the HVR-I encoding sequence. Briefly, after alignment of 100 randomly selected sequences available from GenBank, two sets of primers were designed within the most conserved part of HVR-I flanking regions. First, a PCR using outer primers (sense 5 0 -ATG GCT TGG GAT ATG ATG-3 0 ; antisense 5 0 -TC ATT GCA (G/A)TT CAG GGC AGT CCT GTT-3 0 ) was performed. In the absence of proper amplification, as visualized by gel electrophoresis, a nested PCR using inner primers (sense 5 0 -GCT TGG GAT ATG ATG ATG AAC-3 0 , antisense 5 0 -TGC CA(G/A) CTG CC(G/A) TTG-3 0 ) for the second round was performed. The first round PCR was set by mixing 10 ml of cDNA, with 90 ml of a mix containing 0.5 mM of each outer primer, 1 Â PCR buffer (MgCl 2 1.5 mM), 0.2 mM each dNTP and 2.5 U Taq DNA polymerase (Taq PCR Core Kit; Qiagen, Les Ulis, France). 10 ml of the first round PCR products were used as template for the second round amplification, as described above, except the primers were replaced by the inner set. The two rounds were performed under the same conditions: first cycle of 941C for 3 min, 551C for 30 s, and 721C for 30 s, followed by 40 cycles of 941C for 30 s, 551C for 30 s, and 721C for 30 s.
PCR products were purified with PCR purification gel QIAquick kit (Qiagen, Les Ulis, France), and ligated into TA cloning vectors (Invitrogen, Cergy-Pontoise, France). Recombinant plasmids were then used to transform Escherichia Coli competent cells (TOPO TA cloning Kit for sequencing, Invitrogen, Cergy-Pontoise, France) according to manufacturer's instructions. In all, 16-20 clones per patient were randomly picked on agarose plates. Recombinant plasmids were purified with QIAprep 8 Turbo Miniprep Kit (Qiagen, Les Ulis, France). In all, 3 ml of purified recombinant plasmid were used as template for sequencing, using M13 forward and reverse sequencing primers, with ABI Big dye V3 terminator cycle sequencing ready reaction kit (Applied Biosystems, Les Ulis, France) on an ABI 3100 sequencer.
Sequence analysis
Sequence analysis was performed with SeqScape v2 1.1 program (Applied Biosystems, Les Ulis, France). Nucleotide and deduced peptide sequences were aligned using clustalW, version 1.81 24 and compared with the consensus HVR-I sequence described by Puntoriero et al. 25 To assess HVR-I sequence complexity, the normalized Shannon entropy was calculated as follows: S ¼ ÀS i (p i ln p i ) where p i is the frequency of each sequence in the viral quasispecies. The normalized entropy was calculated using the formula Sn ¼ S/ln N, where N is the total number of sequences analyzed.
Phylogenetic, molecular evolutionary analyses and the number of synonymous and nonsynonymous substitutions per site were conducted using MEGA version 3.0. 26 Phylogenic trees were constructed using the neighbor-joining algorithm and the statistical evaluation of the obtained topology was performed on 1000 replicates by bootstrap resampling.
Statistical analysis
Comparisons between patients with or without B-cell clonal proliferation were performed using Mann-Whitney U-test for quantitative data and Fisher's exact test for categorical variables. Statistical significance was considered at Po0.05. Data were analyzed using NCSS 2001 (Kaysville, UT, USA).
Results
HVR-I amplification and sequencing
Viral RNA was obtained from sera of chronically infected patients stored at À801C. Patients were grouped according to the presence (group I; patients 1-15) or the absence (group II; patients 16-29) of B-cell lymphoproliferation. Patient's characteristics are described in Table 1 . The two groups were not different with regard to age, sex ratio and viral load.
Using our combined set of primers, 50% of patient's samples were amplified through a single PCR (nt 1284-1619), and the remaining required a nested second round amplification (nt 1298-1591). The amplified fragment comprised the entire HVR-I sequence (aa 384-411). A total of 16-20 clones per patient were randomly selected and sequenced. An average of 13 (7-18) sequences per patient was available for further analysis. Nucleotide sequences were aligned, translated and compared to the consensus sequence generated by Puntoriero et al.
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Analysis of HVR-I quasispecies distribution
The distribution of the 385 clones analyzed is shown in Table 1 . The evaluation of HVR-I nucleotide sequences diversity between the two groups was accomplished by calculation of the mean genetic distance within each sample using a Kimura two-parameter distance matrix with a transition to transversion ratio of 2. The nucleotide diversity of both groups was comparable (group I: 0.0374 vs group II: 0.0920, P ¼ 0.190). The ratio of nonsynonymous to synonymous substitutions was lower for patients with BCLD (group I: 0.705 vs group II: 2.139, P ¼ 0.004) ( Table 1 ). The value of this ratio, slightly below 1 for the BCLD group, may reflect an immune pressure selection rather than a natural genetic drift.
Several phylogenetic trees were constructed using the 385 HVR-I nucleotide sequences obtained from the 29 patients. In a same patient, 1-18 different clones were characterized and overall 192 different nucleotide sequences were represented. Each clone corresponded to different variants of HVR-I genetically distinct but closely related and therefore clustered together. Distribution of HVR-I quasispecies from the 29 patients with or without B-cell lymphoproliferative disease was homogeneously spread within the tree and no cluster could be evidenced according to B-cell proliferation. Noteworthy, distribution of the HVR-I sequences from patients who had MC or evidence of B-cell clonality was also homogenous and did not cluster according to the clinical feature (data not shown).
Analysis of HVR-I amino-acid sequences variability
Using a neighbor-joining algorithm coupled with bootstrapping, 134 unique HVR-I amino-acid sequences from all patients were analyzed. As previously seen with the nucleotide sequences, the only significant clustering observed was between sequences from the same patient but it was independent from the presence or not of B-cell lymphoproliferation (Figure 1) . Interestingly, three patients (patients 3, 9 and 12) with a monoclonal B cell proliferation had highly homogeneous quasispecies characterized by only one variant detected within all their clones (Table 2 ). This could highlight a selection process associated with B-cell dysregulation. The complexity of HVR-I was estimated by calculation of the amino-acid normalized entropy. Although the difference did not reach significance, viral population within group I seemed slightly more homogeneous (Sn ¼ 0.347) than in group II (Sn ¼ 0.458) (P ¼ 0.222).
In three patients (patient #7, #16 and #21, all infected with HCV 1b genotype), a single amino acid insertion was detected. Nucleotide sequences alignment revealed the presence of a codon insertion located at the beginning of the HVR-I encoding Hypervariable region of HCV and lymphoproliferation A Rigolet et al region. Translation of the nucleotide sequences resulted in an extra amino acid added between positions 1 and 2 of HVR-I. Patient #7 had a monoclonal B-cell proliferation, defined by the presence of a type II MC, and a glycine insertion was detected in all nine clones analyzed, corresponding to four distinct HVR-I variants. Patients #16 and #21 both belonged to the control group without monoclonal B-cell proliferation, and presented an insertion of respectively a lysine and a histidine at the same position, between positions 1 and 2 of HVR-I. The HVR-I added amino acid was found in all 18 clones for patient #21 (eight distinct variants), while for patient #16 the insertion was observed in only seven clones (four distinct variants) among 12 present in his serum. No other amino-acid insertion or deletion was detected among HVR-I sequences of the remaining 26 patients. As highlighted in Table 2 , three residues were highly conserved at position 6 (G), 23 (G) and 26 (R). The residue at position 2 was also conserved except for one sequence isolated from the control group. In patient 19, belonging to the control group, several clones encoded truncated forms of gpE2; however, the predominant two species, 10 out of 14 clones, encoded the full HVR-I region. When comparing residue frequency at each position of the HVR-I region, the distribution was very alike between the two groups with no particular motif associated with BCLD.
Discussion
Several benign and malignant lymphoproliferative disorders occurring in chronic HCV infection, such as type II MC and nonHodgkin's lymphoma, suggest a possible link between HCV and monoclonal B-cell proliferation. Although a mechanism through which HCV could induce expansion of particular B-cell clones remains unknown, recent studies suggest that the HCV E2 envelope glycoprotein, including the HVR-I region, may be the chronic antigenic stimulus involved in the lymphoma genesis process. 11, 13, 27 Specific amino-acid mutation (385 insertion or 384 deletion, corresponding to residue one or two of our numbering) was detected by Gerotto et al 20 in HVR-I sequence of some Italian patients (6/21) with type II MC. The aim of our study was to ascertain whether specific HVR-I variation occurred in HCV genome of French patients with monoclonal B-cell proliferation.
Sequence analysis of a large number of HVR-I clones from chronically HCV-infected patients with evidence of monoclonal B-cell proliferation (n ¼ 15) or without (n ¼ 14) showed that no HVR-I genetic signature was clearly associated with BCLD. An insertion between residue 1 and 2 of HVR-I, comparable to the one reported by Gerotto et al, 20 was detected in three of our patients. Contrary to the findings of the former publication, this insertion was found in one patient (#7) with a monoclonal B-cell proliferation, that is, a type II MC, but also in two patients (#16 and #21) from the control group. The inserted amino acid is in the first case a glycine and in the second a lysine. Presence of Figure 1 Neighbor-joining phylogenetic trees constructed from 134 HVR-I amino-acid sequences. The scale in genetic distance is indicated and the number of 1000 permuted trees supporting a clade is indicated on a branch when above 50%. Each circle represents a unique sequence from patient with B-cell lymphoproliferation (filled) or from patient belonging to the control group (open). Each patient was numbered (pat ##) and each unique sequence was also given a unique number. The tree was rooted from the reference consensus sequence (open triangle) and the scale is indicated at the left bottom. Table 2 HVR-I amino-acid alignment from patient's clones with and without BCLD The reference sequence (REF) in italic is based on the consensus sequence generated by Puntoriero et al, bold, italic and underlined characters represent highly conserved residue in HVR-I sequences. Dots indicate residues identity, dashes indicate missing residues. The number of identical clones per patient is indicated in the right column.
Hypervariable region of HCV and lymphoproliferation
A Rigolet et al such insertion in two patients with no evidence of monoclonal expansion may exclude the possibility that this amino-acid mutation could play a specific role in lymphoproliferative process occurring during chronic HCV infection. The 385 insertion in HVR-I is a rare mutation in HCV genome (only 2% reported by Gerotto et al among 1345 HVR-I sequences from the GenBank database) whereas almost 50% of HCV-infected patients present an associated cryoglobulinemia. This discrepancy is not in favor of a major influence of this insertion in the development of BCLD. Even though our patient's selection was small, a more thorough analysis did not reveal a particular motive associated with either the clinical aspects of the disease, or the presence of MC or only clonality. The relative lower diversity in patients with BCLD compared to the control group may indicate a decreased immune pressure exerted on the viral quasispecies. Indeed, even though the comparison of normalized entropy between the two groups did not reach statistical significance, in three patients from the BCLD group but in none from the control group, the quasispecies were composed of a unique sequence. The absence of selection could reflect an ineffective humoral immune response and a bias toward the production of a cryoglobulin inactive against the current replicating virus.
The patients from our study were infected by different HCV genotypes (1, 66%; 2 and 3, 21%; 4, 7% and 5, 7%). Interestingly, the three patients exhibiting an HVR-I insertion were infected with genotype 1b, suggesting that this added codon may occur more often with this genotype. A higher frequency of this insertion in genotype 1b patients may explain the prevalence of 24% (5/21) in Gerotto's study and could be due to a genotype bias.
Even though a strong selection pressure to maintain the length of HVR-I has been described, modification of HVR-I length and consequently modification of its conformation is likely to alter gpE2 antigenic properties and its interaction with other molecules such as CD81 or other putative receptors. 28 In the absence of any functional assay, the implications of these changes are difficult to evaluate and their role in the triggering of lymphoproliferative disorders remains to be studied. As proposed by Hofmann et al, 29 site-directed mutagenesis coupled with functional studies may be an elegant approach to elucidate the role of these residue changes. Interestingly, the two residues (4 and 13) described by the former authors were not found with a higher prevalence in our BCLD group of patients. However, the relevance of any primary sequence changes on protein conformation, and therefore interaction with other cell components, may provide some interesting information. 30 In our study, no major change in the hydrophobic or antigenic profiles was found when the consensus amino-acid sequences were compared between each group (data not shown).
The limitation of our study to serum quasispecies may be one explanation for the absence of particular HVR-I motif associated with lymphoproliferation. Indeed, because of the selective distribution of quasispecies within different compartments such as hepatocytes or peripheral blood mononuclear cells, it is possible that a particular strain may be directly involved in infection and stimulation or dysregulation of lymphocytes. 31, 32 In addition, the demonstrated interaction of the envelope glycoproteins E1 and E2 with several other receptors, beside CD81, is likely to depend on specific structural conformation. 28, 33, 34 The role played by HVR-I conserved residues in these receptor interactions may provide some explanations to HCV compartmentalization or to immune-related pathologies.
Also it would be too early to firmly exclude a role of specific residues within HVR-I sequence in the development of lymphoproliferative disorders, our study does not support recent findings regarding a specific motif HVR-I associated with BCLD. Further research should now focus on HVR-I and gpE2 functional studies and clinical studies relying on larger patient groups.
